TENX
Tenax Therapeutics, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C-
Company Profile
CEO
Christopher T. Giordano
IPO Date
1994-04-04
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Tenax Therapeutics, Inc.
CEO
Christopher T. Giordano
IPO Date
1994-04-04
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 450,000 |
| $11.95 |
| 13 May 2026 | STAAB THOMAS R II | Chief Financial Officer | Disposed | 0 | $0.00 |
| 3 Feb 2026 | MCGAULEY THOMAS | Interim CFO | M-Exempt | Acquired | 50,000 | $12.51 |
| 13 Jan 2026 | Davidson Michael H. | director | A-Award | Acquired | 30,000 | $13.30 |
| 13 Jan 2026 | Giordano Christopher Thomas | director, officer: CEO | A-Award | Acquired | 450,000 | $13.30 |
| 13 Jan 2026 | Rich Stuart | director, officer: Chief Medical Officer | A-Award | Acquired | 250,000 | $13.30 |
| 13 Jan 2026 | PROEHL GERALD T | director | A-Award | Acquired | 3,000 | $13.30 |
| 13 Jan 2026 | Almenoff June Sherie | director | A-Award | Acquired | 30,000 | $13.30 |
| 13 Jan 2026 | Doogan Declan | director | A-Award | Acquired | 30,000 | $13.30 |